NICE guidelines on anti-tumor necrosis factor therapy for RA

Nature Clinical Practice Rheumatology volume 5, pages16–17(2009)Cite this article

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1

    Rawlins MD and Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329: 224–227

  2. 2

    Maynard A et al. (2004) Challenges for the National Institute for Clinical Excellence. BMJ 329: 227–229

  3. 3

    National Institute for Health and Clinical Excellence [http://www.nice.org.uk/Guidance/TA130/Guidance/pdf/English] (accessed 6 November 2008)

  4. 4

    Chen YF et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10: 1–229

  5. 5

    Zink A et al. (2006) Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54: 3399–3407

  6. 6

    Greenberg JD et al. (2008) Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 121: 532–538

  7. 7

    Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381–3390

  8. 8

    van Vollenhoven RF (2004) Switching between biological agents. Clin Exp Rheumatol 22 (5 Suppl 35): S115–S121

  9. 9

    Keystone EC (2006) Switching tumor necrosis factor inhibitors: an opinion. Nat Clin Pract Rheumatol 2: 576–577

  10. 10

    Erickson AR and Mikuls TR (2007) Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 9: 416–420

  11. 11

    Bombardieri S et al. (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46: 1191–1199

  12. 12

    Buch MH et al. (2007) Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 57: 448–453

  13. 13

    Hyrich KL et al. (2008) Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 47: 1000–1005

  14. 14

    Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20

  15. 15

    Karlsson JA et al. (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47: 507–513

  16. 16

    Barton P et al. (2004) The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 8: iii, 1–91

Download references

Author information

Affiliations

  1. DL Scott is Professor of Clinical Rheumatology and Honorary Consultant Rheumatologist, and S Steer is a recently appointed Consultant Rheumatologist at King's College Hospital, London, UK.
    • David L Scott
    •  & Sophia Steer
Authors
  1. Search for David L Scott in:
  2. Search for Sophia Steer in:

Corresponding author

Correspondence to David L Scott.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, D., Steer, S. NICE guidelines on anti-tumor necrosis factor therapy for RA. Nat Rev Rheumatol 5, 16–17 (2009) doi:10.1038/ncprheum0964

Download citation

Further reading